GLP-1 Medications for Weight Loss: A Clinical Overview

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·12 min read

GLP-1 medications are the reason medical weight loss looks different today than it did even a few years ago. For the first time, clinicians have pharmacologic tools that produce durable, clinically meaningful weight loss in a field where most older options were modest, short-lived, or poorly tolerated. This guide is the weight-loss-clinic view of that class: how it fits a practice, how to choose among the agents, and what to monitor. For the deep pharmacology of each individual molecule, it links out to Empire's dedicated compound guides rather than repeating them here.

This page situates GLP-1 therapy within the broader practice of medical weight loss and the science of peptide therapy. It is clinical education for providers, not medical advice, and nothing here should be read as a treatment recommendation, protocol, or substitute for current FDA labeling.

What are GLP-1 medications?

GLP-1 agonists are a class of medications initially developed to treat type 2 diabetes that have since proven highly effective for weight loss. The shared mechanism is that they imitate glucagon-like peptide-1 (GLP-1), a hormone the body naturally produces in the intestines and the brainstem after eating. That single fact — these are gut hormones in drug form — explains nearly everything about how they behave.

GLP-1 belongs to the family of incretins, the gut signals that tell the pancreas food is on the way. When food is eaten, the intestine releases GLP-1, which increases insulin secretion in response to the meal, helps lower blood sugar, slows the rate at which the stomach empties, and acts on the brainstem and hypothalamus to reduce appetite and increase fullness. Native GLP-1 breaks down within minutes, which limited its early usefulness; the modern agents are engineered to resist that rapid breakdown, which is why most are administered as a once-weekly injection. In short, GLP-1 medications restore and amplify a normal post-meal satiety signal pharmacologically.

How GLP-1s work for weight loss

It is more accurate to tell patients that GLP-1 weight loss runs through several parallel mechanisms than to credit a single one. The first is central: by acting on the brainstem and the hypothalamus, GLP-1 agonists decrease appetite and increase feelings of fullness after meals. Many patients describe the constant intrusive thoughts about food — often called “food noise” — quieting within the first weeks, which is frequently what makes adherence to a diet finally feel possible.

The second is mechanical. GLP-1 agonists slow gastric emptying, the rate at which the stomach releases its contents into the small intestine. That produces faster, longer-lasting fullness after meals and a more gradual absorption of glucose into the bloodstream. The third is metabolic: by enhancing glucose-dependent insulin secretion and blunting post-meal glucose and insulin surges, the medications shift the body toward mobilizing fat rather than storing it. Together these effects reduce caloric intake without the white-knuckle hunger that sinks most diets.

A point Empire's faculty stresses is that this is systemic, not targeted. Fat reduction occurs throughout the body, including the face — the phenomenon patients have nicknamed “Ozempic face” — which is worth raising at consultation so the cosmetic trade-off is understood up front. Sharing this full framework early helps patients stay the course when weight loss naturally plateaus, because they understand the drug is changing physiology, not performing magic.

The agents: semaglutide, tirzepatide, retatrutide

A weight-loss practice does not need to memorize every molecule in the pipeline, but it should understand the three that define the field. Each has its own dedicated compound guide in Empire's peptide library; the summaries below are orientation, and the links are where the full pharmacology, dosing context, and labeling live.

Semaglutide (Wegovy)

Semaglutide is the established single-pathway GLP-1 receptor agonist and the most studied agent in medical weight loss. It is FDA-approved as Wegovy for chronic weight management and as Ozempic and Rybelsus for type 2 diabetes, and it has been associated with up to roughly 16% weight loss over placebo in clinical studies — a significant advance in the treatment of obesity. For the full mechanism, brands, dosing context, and safety detail, see our semaglutide clinical guide.

Tirzepatide (Zepbound)

Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — a second incretin pathway. By engaging both, it suppresses appetite, reduces hepatic glucose output, and slows gastric emptying, and in clinical trials it has produced weight loss often exceeding that seen with GLP-1 receptor agonists alone. It is FDA-approved for weight management as Zepbound. See our tirzepatide clinical guide for the full dual-incretin picture.

Retatrutide (investigational)

Retatrutide is an experimental agent from Eli Lilly that mimics GLP-1 and GIP plus glucagon — a triple-mechanism approach — and in a mid-stage trial participants lost an average of about 24% of body weight. It is genuinely promising but not FDA-approved and should be discussed with patients as investigational. Our retatrutide guide covers what is and is not yet known.

Efficacy and the evidence base

What separates GLP-1 medications from the long history of weight-loss drugs is the depth of the evidence behind them. The STEP program evaluated semaglutide for weight management across distinct populations — non-diabetic obesity, type 2 diabetes with obesity, and regimens pairing the drug with intensive behavioral therapy — and showed a consistent pattern of clinically meaningful weight loss, with patients who have diabetes generally losing somewhat less than those without. The SURMOUNT trials did the same for tirzepatide, where the dual-incretin mechanism translated into even larger average reductions.

Beyond weight, the SELECT trial showed that semaglutide reduced major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity — notably without requiring diabetes for entry. That moved GLP-1 therapy from a weight-and-glucose story into a cardiovascular one, and it expanded who is an appropriate candidate.

The single most important caveat to share with patients concerns durability. Trial data show that patients who continue therapy tend to maintain their loss, whereas those who discontinue tend to regain a substantial portion of it. This reframes the conversation entirely: GLP-1 medications are best understood not as a temporary course but as treatment for obesity as a chronic, relapsing disease — much as one does not stop an antihypertensive once blood pressure normalizes. The decision to continue should rest on the individual's degree of weight loss, health improvements, and tolerability.

Side effects and safety

GLP-1 agonists are effective, but they are not without risk, and prescribing competence is largely about managing that risk well. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and they are tightly linked to slowed gastric emptying and to dose escalation. The guiding clinical principle is to escalate slowly: advance only when the current step is tolerated, counsel patients in advance that symptoms tend to peak with each new step and then subside, and step back rather than stop when symptoms appear. Practical adjuncts include smaller meals, avoiding high-fat fried foods during escalation, and adequate hydration.

Beyond common GI effects, FDA labeling describes more serious considerations that must be screened in every patient. There is a boxed warning regarding thyroid C-cell tumors based on rodent findings, and these agents are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). There have been reports of acute pancreatitis associated with GLP-1 therapy, though a definitive causal relationship has not been established. Because they slow gastric emptying, they are cautioned in severe GI disease such as gastroparesis, and they are generally avoided in pregnancy and end-stage renal disease.

Deliberately, this overview does not publish specific doses, titration schedules, or exact incidence figures — those belong to current labeling and individualized judgment, and they are covered step by step in Empire's training. The responsible summary is that these are well-studied medications with a defined, manageable risk profile that nonetheless require proper patient selection, monitoring, and prescriber competence.

Lean-mass preservation

The most under-appreciated part of GLP-1 prescribing is what comes off with the fat. Rapid weight loss — from any cause, including these medications — carries away a meaningful fraction of lean muscle mass along with adipose tissue, which is the opposite of the metabolic goal and especially consequential as patients age and frailty and fall risk climb. Dr. Greenleaf frames the physiology bluntly in the course: the body interprets aggressive caloric restriction as stress or famine and will hold on to weight and break down protein, so adequate protein intake is needed to prevent muscle loss during weight loss.

The practical implication is that every GLP-1 prescription should travel with two non-negotiable companions: resistance training and a deliberate, adequate protein intake. The medication is the lever; the patient's training and nutrition are the load it acts on. A weight-loss program built around GLP-1 therapy that ignores muscle is leaving the patient lighter but metabolically worse off — and a slower, supported rate of loss generally preserves lean mass better than a crash.

Compounded GLP-1 caution

Because branded supply has at times been constrained, compounded GLP-1 products proliferated — and they sit in a far more complicated and shifting regulatory position than the FDA-approved branded medications. The FDA has taken regulatory action that can lead to actions against pharmacies using certain substances, which has in turn raised real concern about patient access. The honest guidance for providers is caution: compounded GLP-1 products are not equivalent to the approved versions, sourcing and quality vary, and the regulatory landscape continues to change. Any clinician considering them must understand the current rules before acting, and should document that reasoning. The compounding question is covered in more depth in our semaglutide guide.

Their place in a weight-loss practice

GLP-1 medications are powerful, but they are one component of a comprehensive program, not the program itself. Patient selection follows FDA labeling — broadly, a BMI at or above 30, or at or above 27 with a documented weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea — with the SELECT-derived cardiovascular population as a distinct eligibility lane. Off-label use in normal-weight patients for cosmetic loss is an area to approach with genuine caution.

Within the practice, GLP-1 therapy sits alongside the rest of the medical weight loss toolkit: structured nutrition, the non-GLP-1 weight loss medications for patients who are not candidates or who need adjuncts, and the foundational framing of obesity as a disease. The clinician's job is to position the medication correctly, protect lean mass, monitor for the defined risks, and set honest expectations about duration and what happens if therapy stops. Done well, this is one of the highest-impact services a modern practice can offer.